CAL
RETA

Capital Advisors Ltd’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Capital Advisors Ltd’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 1618
2022
Q2 		$0 Sell
2
-6
-75% -$179 ﹤0.01% 1420
2022
Q1 		$0 Buy
+8
New +$237 ﹤0.01% 1290

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Advisors Ltd's RETA Position: Q3 2022 in Review

Capital Advisors Ltd sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2022, closing a stake of 2 shares.

Capital Advisors Ltd first reported a position in RETA in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 159 funds tracked by Wall St. Rank hold RETA as of Q3 2022.

  • Capital Advisors Ltd reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2022 after selling out during the quarter.
  • Capital Advisors Ltd sold 2 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2022.
  • Capital Advisors Ltd first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2022 and held it in 2 quarters.
  • Capital Advisors Ltd's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $0 in Q2 2022.
  • 159 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2022.

Based on Capital Advisors Ltd's 13F filing for Q3 2022, filed 9 Nov 2022.